SH

Scott Harris

Chief Development and Operations Officer

Terns Pharmaceuticals

Therapeutic Areas

Terns Pharmaceuticals Pipeline

DrugIndicationPhase
TERN-701Chronic Myeloid Leukemia (CML)Phase 1